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Diagnosis of bladder pain syndrome/interstitial cystitis (BPS/IC) is presently based on mainly clinical symptoms. BPS/IC can
be considered as a worst-case scenario of bladder overactivity of unknown origin, including bladder pain. Usually, patients
are partially or completely resistant to anticholinergic therapy, and therapeutical options are especially restricted in case of
BPS/IC. Therefore, early detection of patients prone to develop BPS/IC symptoms is essential for successful therapy. We propose
extended diagnostics including molecular markers. Diﬀerential diagnosis should be based on three diagnostical “columns”: (i)
clinical diagnostics, (ii) histopathology, and (iii) molecular diagnostics. Analysis of molecular alterations of receptor expression
in detrusor smooth muscle cells and urothelial integrity is necessary to develop patient-tailored therapeutical concepts. Although
more research is needed to elucidate the pathomechanisms involved, extended BPS/IC diagnostics could already be integrated into
routine patient care, allowing evidence-based pharmacotherapy of patients with idiopathic bladder overactivity and BPS/IC.
1.Introduction
There is an ongoing lively discussion about the diagnosis of
interstitial cystitis (IC). Diagnosis mainly relies on clinical
symptoms, since it has been shown that the more restrictive
deﬁnition of the National Institute of Diabetes, Digestive,
and Kidney Diseases (NIDDK) [1]f a i l e dt od e t e c ta b o u t
60% of the clinically signiﬁcant IC patients [2]. Recently,
IC has been redeﬁned by the European Society for the
Study of Interstitial Cystitis (ESSIC), which felt that bladder
pain or discomfort to be most important criterion for dif-
ferential diagnosis and inaugurated the term bladder pain
syndrome/interstitial cystitis (BPS/IC) [3] .H o w e v e r ,an u m -
ber of alterations within the bladder wall, regarding detrusor
smooth muscle cells [4–7], suburothelial myoﬁbroblasts [8–
10], innervation [11–14], urothelial function and integrity
[15–19], and cytokine expression [20, 21], have been desc-
ribed, implying that pain symptoms develop relatively late in
thecauseofthedisease.Wehypothesizethatinitialurothelial
impairment (unknown origin) initiates a pathophysiological
cascade leading in long-term to the development of BPS/IC,
and that severe pain symptoms are only present in late phase,
that is, full blown clinical picture (Figure 1).
If patients could be detected at an early stage of the
disease, the chance of successful therapeutical intervention
would improve. Therefore, we examined patients showing
clinical symptoms of BPS/IC to ﬁnd a pattern of alterations
associated with BPS/IC.
Sincethewholebladderwallseemstobeinvolvedinblad-
der dysfunction, it is necessary to evaluate urothelial integ-
rity, detrusor smooth muscle cell receptor expression, alter-
ations in the lamina propria, and aﬀerent nervous control.
Weherepropose adiagnostic approachintegrating threedia-
gnostic “columns”, (i) clinical diagnosis, (ii) histopathology,































Figure 1: Hypothetical course of BPS/IC development. While urge-
ncydevelopsinearly“manifestation”phase,painsymptomsbecome
evident only in late “end” phase, deﬁning full-blown BPS/IC.
2.MaterialsandMethods
The study was approved by the local Ethics Committee of the
University of Leipzig and followed the recommendations of
the Helsinki declaration (1964).
Female patients from our hospital were included into a
preliminary study of receptor expression analysis; BPS/IC:
n = 19; age 61.95 (3.164) years, mean (SEM); ESSIC classi-
ﬁcation: 2A (0), 2B (4), 2C (8), 2X (7); control: n = 9; age
63.19 (3.019) years; female patients undergoing cystectomy
due to bladder carcinoma or gynecological tumors. In
a second study, we compared the expression of human
chorionic gonadotropin; control: n = 5; age 62.00 (4.615)
years; BPS/IC: n = 10; age 59.50 (1.881) years; ESSIC classi-
ﬁcation CX (4), 2A (1), 2B (1), 2C (2), and 2X (2).
We used confocal immunoﬂuorescence analysis to quan-
tify the expression of muscarinic (M2, M3), puriner-
gic (P2X1, P2X2, P2X3), histamine (H1, H2) receptors,
and HCG-beta (Table 1) and used SYBR-green quantita-
tive real-time PCR to examine receptor gene expression
(Table 2). Confocal images were acquired at a Pascal 5
laser scanning microscope equipped with a 63 × 1.4na
oil immersion objective (Zeiss, Jena, Germany). Analyses
were done using self written ImageJ [22] scripts, OpenOﬃce
(http://www.OpenOﬃce.org/), and GraphPad Prism version
5 for Mac OS X (GraphPad Software, San Diego, Calif, USA,
http://www.graphpad.com/) was used for statistics.
3. Results andDiscussion
3.1. Symptoms of Bladder Pain Syndrome/Interstitial Cystitis
(BPS/IC). Clinically, frequency, urgency, and bladder pain
are characteristic for patients suﬀering from IC. In the
early stages of the disease, urgency seems to be the most
impressive symptom, and bladder pain develops in later
phase, probably in conjunction with advanced urothelial
damage and perineuronal inﬂammation (Figure 1). In the
“latent” and early “manifestation” phase, it is essential to
distinguish motoric detrusor overactivity from developing
BPS/IC. Urodynamics can help to perform diﬀerential
diagnosis; however, urgency reported by the patient does not
always correlate with urodynamical ﬁndings. Therefore, we
suspect a signiﬁcant part of the patients diagnosed with OAB
syndrome to suﬀer from an early stage of BPS/IC.
An indirect proof for the signiﬁcance of urothelial
damageforthepathophysiologyoftheOABsyndromecomes
from a study showing higher rate of symptoms improvement
after additional application of chondroitin sulfate than by
anticholinergic therapy alone [23]. Chondroitin sulfate is
instilled into the bladder to restore the glycosaminoglycan
(GAG)layeroftheurothelium,whichispartoftheprotective
urine-tissue barrier of the intact urothelial lining [19].
Therefore, urothelial lesion seems to be the best candidate
event for initialization of chronic abacterial cystitis. In
case of therapeutical failure of anticholinergics, diﬀerential
diagnostics of BPS/IC should be performed.
3.2. The Three “Columns” of IC-Diagnostics. We feel that it
is essential to early include histopathological and molecular
biological examination of bladder biopsies into the diag-
nostic regime. Since all cellular components of the bladder
seem to be involved in pathophysiology of BPS/IC, only
histological examination of deep biopsy, spanning the whole
bladder wall, ensures proper diagnosis.
(i) Cystoscopy. Despite common patient symptom report,
frequency, urgency, and bladder pain, the cystoscopic picture
of the bladder might vary considerably (Figure 2). Only
in two cases, cystoscopic evaluation would support BPS/IC
diagnosis (Figures 2(b) and 2(c)), while the other bladder
shows hypervascularization (Figure 2(a)).
Despite this heterogenic cystoscopic appearance, the
endoscopic evaluation of the bladder mucosa including the
vascularization status reveals valuable information. There-
fore, cystoscopy should be included into the diagnostic
routine for OAB diagnostics. The description of a patholog-
ical cystoscopic ﬁndings is essential for early therapeutical
conception before pain becomes the dominant symptom of
a uncontrollable disease. During this stage of disease often,
a clinically hard-to-deﬁne urgency component dominates,
which is, therefore, referred to as “idiopathic urgency”.
Due to the fact that BPS/IC is mostly regarded as pain
syndrome and not as a disease associated with the end
organ urinary bladder, cystoscopic diagnostics and bladder
provocation tests, which are able to detect defects in the
urotheliallayer,havecomeoutoffocusrecently.Therefore,in
thenextchapters,wewilldiscusstherelevanceofhistopatho-
logical alterations within the bladder wall for the diﬀerential
diagnosis of BPS/IC. There are two contrary diagnostic
approaches, the strategy to pure clinical diagnostics and the
concept to evaluate pathological alterations in the diﬀerent
functionalunitsofthebladderwall,whichrequires,however,
invasive diagnostics.
(ii) Histopathology. Histopathological examination should
be obligatory to enable exclusion of carcinoma in situ (cis).
There is no common histomorphological appearance of IC
[24–26]. In the early stage of disease, the urothelial lining
might be normal, and mastocytosis of the detrusor, initiallyAdvances in Urology 3
Table 1: Antibodies used in indirect confocal immunoﬂuorescence.
(a) Primary antibodies
Primary antibodies Host Source Order no. Dilution
M2, muscarinic receptor rabbit [1] AS-3721S 1:1000
M3, muscarinic receptor rabbit [1] AS-3741S 1: 1000
P2X1, purinergic receptor rabbit [2] ab10248 1:1000
P2X2, purinergic receptor rabbit [2] ab10266 1:1000
P2X3, purinergic receptor rabbit [2] ab10269 1:1000
H1, human histamine receptor 1 rabbit [3] H1R12-A 1:250
H2, human histamine receptor 2 rabbit [3] H2R22-A 1:250
HCG (beta-1 epitope) mouse, IgG1 [5] MCA19 1:500
HCG (beta-2 epitope) mouse, IgG1 [5] MCA329 1:20
alpha-smooth muscle cell actin mouse, IgG2a [4] A2547 1:2000
(b) Secondary antibodies
Secondary antibodies Source Order no. Dilution
Alexa Fluor 488 goat antimouse IgG2a invitrogen A-21131 1:500
Alexa Fluor 555 goat antirabbit invitrogen A-21428 1:500
Alexa Fluor 555 goat antimouse invitrogen A-21127 1:500
[1] Research & Diagnostic Antibodies, North Las Vegas, USA.
[2] Abcam Inc., Cambridge, USA.
[3] Alpha Diagnostic Intl. Inc., San Antonio, USA.
[4] Sigma-Aldrich Chemie GmbH, Steinheim, Germany.
[5] AbD Serotec, MorphoSys AG, Martinsried/Planegg, Germany.
Table 2: Primers used for real-time PCR.
Primer Sequence 5  → 3  Product length (bp) Binding site AccNo
h36B4 forward AACATGCTCAACATCTCCCC 397 exon 6 NR 002775.1
h36B4 reverse CCGACTCCTCCGACTCTTC exon 8
aSMCA forward CCAACTGGGACGACATGGAAA 212 exon 4 NM 001613.2
aSMCA reverse GCGTCCAGAGGCATAGAGAGACA exon 6
M2 forward CTAAGCAAACATGCATCAGAATTGG 288 exon 6 NM 001006632.1
M2 reverse AAGGTGCACAAAAGGTGTTAATGAG exon 6
M3 forward ACCCAGCTCCGAGCAGATGGAC 341 exon 5 NM 000740.2
M3 reverse CGGCTGACTCTAGCTGGATGGG exon 5
P2×1 forward GCGTAATAAGAAGGTGGGCGTTA 109 exon 1 NM 002558.2
P2×1 reverse GCCGCTCGAGGTCTGGTA exon 2
P2×2 forward CAGGTTTGCCAAATACTACAAGATCA 105 exon 8 NM 174873.1
P2×2 reverse AACTTCCCGGCCTGTCCAT exon 9
P2×3 forward TCTTCACCTATGAGACCACCAAGTC 83 exon 1 NM 002559
P2×3 reverse GATCAGAAGCTGAACTACTCGGTTGAT exon 1
H1 forward AAGTCACCATCCCAAACCCCCAAG 151 exon 3 NM 001098213
H1 reverse TCAGGCCCTGCTCATCTGTCTTGA exon 3
H2 forward AGGAACGAGACCAGCAAGGGCAAT 198 exon 2a NM 022304
H2 reverse GGTGGCTGCCTTCCAGGAGCTAAT exon 2a
h36B4 = human acidic ribosomal protein P0; aSMCA = alpha-smooth muscle cell actin.4 Advances in Urology
(a) (b) (c)
Figure 2: Cystoscopic images of patients showing identical BPS/IC symptoms. Note the heterogeneity of the appearance of the mucosa
and the diﬀerences in vascularization. (a) Hypervascularization of the bladder wall. (b) Atrophic bladder wall with petechial bleedings after
bladder distension. (c) Ulcerative form of BPS/IC.
used to deﬁne BPS/IC [2, 27], might be absent even in late,
full-blown BPS/IC. An early-stage nonulcerative form (i.e.,
Figures 2(a) and 2(b)) can be discerned from a late-stage
ulcerative form (Figure 2(c)). Histopathological ﬁndings
supporting the diagnosis of BPS/ICare the following.
(1) Urothelial lesions may be present as loss of covering
umbrella cells, urothelial ﬂattening, or urothelial
denudation. The characteristic ﬁnding of urothelial
cracking after hydrodistention can be ascribed to
those histopathological alterations of the urothelial
covering of the bladder wall.
(2) Fibrosis of the mucosa, often reaching the muscular
layer is found especially in late stages of BPS/IC and
accounts for reduced bladder capacity. The ﬁbrosis
proceeds with the progression of the disease and is
related to chronic inﬂammation of the bladder wall.
(3) Interstitial chronic lymphoplasmacellular inﬁltration
of the lamina propria is a characteristic ﬁnding in
most of the patients. In addition, about 70% of
theBPS/ICpatientsshowperineuronalinﬂammation
[26, 28, 29]. Especially at later stages of the dis-
ease, inﬂammatory inﬁltrates are also present within
the detrusor muscle. However, mastocytosis of the
mucosa and the detrusor muscle, which has been
regarded as BPS/IC-speciﬁc feature [30, 31], seems to
be not necessarily associated with BPS/IC [2, 24, 32].
(4) Nerve ﬁber proliferation in the lamina propria and
the detrusor muscle is another common histopatho-
logical ﬁnding in BPS/IC and is regarded as a
major neuropathological factor [11, 33, 34]. How-
ever, despite neural upregulation contributes to the
pathophysiology of BPS/IC, it is still unclear whether
it is a causative factor of BPS/IC or an after-eﬀect.
(5) Hypovascularization of the urothelial layer has been
described[35]andmayaccountforimpairedbladder
perfusion [36, 37] along with wall thickening of
small blood vessels in the submucosa and edematous
alterations.
(iii) Molecular Diagnostics. Few studies examined regulation
of neurotransmitter receptors in the normal and diseased
human bladder. Alterations of receptor expression on var-
ious cells of the bladder wall including nerve ﬁbers have
been demonstrated in OAB [38, 39], idiopathic detrusor
overactivity (IDO) [4, 34, 40], neurogenic bladder [41], and
interstitial cystitis [5, 12].
Since muscarinic receptors on detrusor smooth muscle
cells are the classical target for anticholinergic therapy, we
included the expression of M2 and M3 subtypes in the
receptor analysis of the detrusor. In addition, purinergic
signaling is the second major contributor to detrusor mass
contraction.Atropine-resistant,ATP-mediateddetrusorcon-
tractions have been shown to increase with age [42].
Histamine can evoke calcium transients in cultured human
detrusor smooth muscle cells [43], and histamine receptors
have been the target of IC therapy with H1 [44]o rH 2[ 45]
selective antihistaminics. Therefore, we routinely analyze the
expressionofmuscarinic(M2,M3),purinergic(P2X1,P2X2,
P2X3), and histamine (H1, H2) receptors in the detrusor
smooth muscle cells by confocal immunoﬂuorescence. In
doubleimmunolabelingwithalpha-smoothmusclecellactin
(aSMCA), which is located directly beneath the cellular
membrane of detrusor myocytes, quantiﬁcation of receptor
immunoﬂuorescence could be restricted to receptors located
in cell membrane. Individual receptor expression proﬁles are
generated (Figure 3), and based on those, we developed a
tailored therapy concept.
The use of routine formalin-ﬁxed bladder tissue has the
advantage that there is no need for sophisticated probe pre-
paration and retrospective studies can be conducted on
archive material.
Theconceptof tailoredtherapy basedonmoleculardiag-
nostics has already been established for other disease entities,
for example, colon carcinoma [46], and is a most promising
approach in cancer management [47].
We also used quantitative real-time PCR (qPCR) to add-
ressreceptorgeneexpression.However,wefoundnocorrela-
tionbetweenqPCRandproteinexpression(datanotshown),


































































Figure 3: Examples of individual receptor expression proﬁles based on confocal immunoﬂuorescence analysis. (a–c) showing a female
patient with overexpression of M3, P2X1-3 receptors; (d–f) typical distribution in IC patients with overexpression of M2 receptor; in
addition,thispatientshowshighlevelsofpurinergicreceptorsandsigniﬁcantexpressionofhistamineH2receptor;aSMCA(green);receptor
staining (red); nuclear staining (blue); bar in (a) applies to all micrographs; (c, f) mean ± SD; bars indicate signiﬁcant diﬀerences (ANOVA,
Tukey’s Test, P<0.05).
(1) BPS/IC Patients Show a Distinct Detrusor Mus-
cle Receptor Pattern. Confocal immunoﬂuorescence-
based receptor proﬁling revealed distinct upregu-
lation of muscarinic (M2) and purinergic (P2X1,
P2X2) receptors in BPS/IC patients compared to the
control group (Figure 4).
(2) Muscarinic Receptors. BPS/IC bladders showed signi-
ﬁcant upregulation of muscarinic M2 receptor (P =
0.0105, Mann-Whitney test), which was also signif-
icantly higher than the M3 receptor in the detrusor
of those patients (P = 0.0021, Wilcoxon signed rank
test). In contrast, control detrusor showed equal
expression of M2 and M3 receptors. In a small frac-
tionof patients (3/19patients, 16%),the M3receptor
expression was signiﬁcantly higher than that of M2
muscarinic receptor. Numerous studies have shown
that M3 selective anticholinergics are not superior to
nonselective anticholinergic in respect to reduction6 Advances in Urology






























Figure 4: Comparison of the receptor expression in detrusor biopsies from age-matched patient collectives (control n = 9; BPS/IC n = 19).












































Figure 5: HCG-beta (beta-2 epitope) immunoreactivity in urothelium. (a) Control bladder from a 36-year-old woman, gynecologic tumor,
no bladder carcinoma; (c) BPS/IC bladder of a 53-year-old woman showing extreme upregulation of HCG-beta; bar in (a) applies to (a
and b); (c) Quantitative analysis revealed signiﬁcant diﬀerences between female controls (n = 5) and female BPS/IC (n = 10) patients
(Mann-Whitney test, P<0.05).
of OAB symptoms. We suppose that this might in
part be due to heterogeneity in muscarinic receptor
expression in the patients collectives examined. Pres-
election of patients by their M2/M3 receptor expres-
sion status might, therefore, improve anticholinergic
therapy.
(3) Purinergic Receptors. Purinergic P2X receptors are
expressed on detrusor smooth muscle cells and
mediate atropine-resistant, ATP-evoked detrusor
contractions [49, 50]. Unfortunately, to date, subtype
selective antipurinergic drugs are not available for
therapy. However, patients with overexpression of
P2X receptors showed good response to botulinum-
toxin A (BoNT-A) injection therapy. BoNT-A is
thought to inhibit both eﬀerent motor nerves and
aﬀerent sensory nerve [51]. Our own preliminary
studies of BoNT-A eﬀect on the receptor expression
in the bladder speak in favor of a modulation of
receptor expression in detrusor smooth muscle cells
(preliminary report [52]).
(4) Histamine Receptors.I no u rc o l l e c t i v e ,b o t hH 1
and H2 histamine receptor subtypes were slightly
upregulated (Figure 4), however, without reaching
signiﬁcance level. The expression showed high
individualvariability(H1>H2(6);H1=H2(10);H2
> H1 (3)) and 3 patients showed exceptionally high
histamine receptor expression in the range of M3 or
purinergic receptor expression. Antihistaminic ther-
apy using H1-selective or H2-selective antihistaminic
drugs was based on the ﬁnding of enhanced mast
cell inﬁltration in IC patients [53]. Unfortunately,
the outcome of the studies varied considerably.Advances in Urology 7
Therefore, antihistaminic therapy has not been
established widely as therapeutic option. Histamine
receptors are expressed in detrusor smooth muscle
cells and might be highly overexpressed in individual
cases. Histamine can evoke calcium transients in
cultured human bladder smooth muscle cells
[43, 54] and detrusor contractions [55]. Therefore,
antihistaminics may act directly on detrusor smooth
muscle cells. The heterogeneity of histamine receptor
expression may well account for the high variability
of therapeutical success. In case of upregulation, H1
or rather H2 antagonists would promise maximal
eﬀect of antihistaminic therapy, which might be used
in combination with receptor expression-adapted
anticholinergics.
(5) MolecularDiagnosticsoftheBladderUrothelium.BPS/
IC is a disease of the complete bladder wall, including
detrusor,submucosa,andurothelium.Therefore,itis
essential to include pathology of the diﬀerent cellu-
lar components into BPS/IC diﬀerential diagnosis.
Despite pathology of the urothelium are most pro-
minentincystoscopicexaminationandbreakdownof
the urothelial urine-tissue barrier is well recognized
asmajorpathophysiologicalfactorinBPS/IC,cellular
alterations have not been investigated intensively.
Based on our own clinical experience, we examined
the expression of human chorionic gonadotropin
beta (HCG-beta) in the urothelium of BPS/IC and
control patients. An interesting, still not explainable
phenomenon is the clinical observation that IC sym-
ptoms ameliorate in female patients during preg-
nancy or infertility treatment with (HCG-beta). We
found expression of HCG-beta in the urothelium
throughout the urinary tract. Interestingly, HCG-
beta is expressed in females and males, which indi-
cates a new, unknown function of this hormone.
HCG-beta can no longer be regarded as pregnancy-
related hormone or tumor marker, since meanwhile
our research group found constitutive expression
of HCG-beta in bowel and eye (unpublished data).
Two distinct HCG-beta isoforms, which are coded
by diﬀerent genes: type 1 (HCG-beta 6,7) and type 2
(HCG-beta 3,5,8) are diﬀerentially expressed throug-
hout the body [56]. While type 2 is expressed in pla-
centa and in malignant tumors, type 1 is expressed in
nontrophoblasttissues.Itisespeciallyinterestingthat
the endometrial production of HCG-beta varies in
the female during normal menstrual cycle, reaching
maximal concentrations in the late secretion phase
[57, 58]. The eﬀect of HCG-beta in the endometrium
includes cell diﬀerentiation and neovascularization
and might serve as a model for the restoration of
urotheliallininginBPS/IC.Inapreliminarystudy,we
found upregulation of HCG-beta in the urothelium
of nonpregnant BPS/IC women and also in men
(Figure 5). Restoration of the destructed urothelial
barrier in BPS/IC could be promoted by HCG-beta
therapy and would be a causal therapeutical concept.
4. Conclusions
BPS/IC is a complex bladder dysfunction involving all cel-
lular layers of the bladder. Current medicinal therapies lack
consistentsuccess.Weproposeadiagnosticalconceptinclud-
ing cystoscopic examination, histopathological evaluation,
and the assessment of neurotransmitter expression proﬁle to
develop a tailored BPS/IC therapy.
Based on the expression levels of muscarinic receptors,
it seems likely that patients with M3 receptor overexpression
would proﬁt most from M3 selective anticholinergics, while
unselective anticholinergics may be the better choice for
patients showing high levels of M2 receptors, as found in
the majority of BPS/IC patients in our study. In case of
signiﬁcant histamine receptor expression, subtype selective
antihistaminic therapy should be tried. Patients resistant
to anticholinergic therapy might also proﬁt from BoNT-A
injection therapy, which might be a good choice especially if
purinergic receptors are overexpressed. We further propose
the evaluation of human chorionic gonadotropin expression
in urothelial cells, which might lead to new therapeutical
options for BPS/IC treatment.
To date, it seems likely that BPS/IC patients would pro-
ﬁt most from combination of various receptor inhibitors
adapted to their individual receptor proﬁle. In addition,
urothelial regeneration could be the clue to long-lasting suc-
cess in BPS/IC therapy. There is a urgent need for clinical
studies to verify the beneﬁt of tailored therapy concept
proposed here.
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